1. Home
  2. MDGL vs FCN Comparison

MDGL vs FCN Comparison

Compare MDGL & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • FCN
  • Stock Information
  • Founded
  • MDGL 2011
  • FCN 1982
  • Country
  • MDGL United States
  • FCN United States
  • Employees
  • MDGL N/A
  • FCN N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • FCN Professional Services
  • Sector
  • MDGL Health Care
  • FCN Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • FCN Nasdaq
  • Market Cap
  • MDGL 6.4B
  • FCN 7.0B
  • IPO Year
  • MDGL N/A
  • FCN 1996
  • Fundamental
  • Price
  • MDGL $340.14
  • FCN $191.79
  • Analyst Decision
  • MDGL Buy
  • FCN Strong Buy
  • Analyst Count
  • MDGL 14
  • FCN 1
  • Target Price
  • MDGL $351.67
  • FCN $275.00
  • AVG Volume (30 Days)
  • MDGL 392.5K
  • FCN 198.9K
  • Earning Date
  • MDGL 02-26-2025
  • FCN 02-20-2025
  • Dividend Yield
  • MDGL N/A
  • FCN N/A
  • EPS Growth
  • MDGL N/A
  • FCN 28.86
  • EPS
  • MDGL N/A
  • FCN 8.71
  • Revenue
  • MDGL $76,813,000.00
  • FCN $3,728,412,000.00
  • Revenue This Year
  • MDGL N/A
  • FCN $7.62
  • Revenue Next Year
  • MDGL $195.95
  • FCN $4.98
  • P/E Ratio
  • MDGL N/A
  • FCN $22.18
  • Revenue Growth
  • MDGL N/A
  • FCN 11.66
  • 52 Week Low
  • MDGL $168.25
  • FCN $185.93
  • 52 Week High
  • MDGL $368.29
  • FCN $243.60
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 61.81
  • FCN 44.70
  • Support Level
  • MDGL $266.44
  • FCN $190.31
  • Resistance Level
  • MDGL $343.97
  • FCN $195.44
  • Average True Range (ATR)
  • MDGL 20.88
  • FCN 3.88
  • MACD
  • MDGL 2.00
  • FCN 0.33
  • Stochastic Oscillator
  • MDGL 92.59
  • FCN 29.96

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

About FCN FTI Consulting Inc.

FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance and restructuring, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.

Share on Social Networks: